Fig 1.
Population impact of vaccination on dengue cases and hospitalizations.
Percentage of reported dengue cases averted by targeted age groups under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios, and percentage of hospitalizations due to dengue averted by targeted age groups under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, for three different vaccine coverage levels, over a 10-year routine vaccination program with Qdenga. Solid dots represent the mean model projections, and error bars indicate the corresponding 95% range of simulations.
Fig 2.
Impact of vaccination on dengue cases and hospitalizations stratified by baseline serostatus.
Percentage of reported dengue cases averted by targeted age groups under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios, and percentage of hospitalizations due to dengue averted by targeted age groups under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, for the whole population, seropositive individuals only, and seronegative individuals only, assuming 80% vaccine coverage, over a 10-year routine vaccination program with Qdenga. Bars represent mean model estimates, and error bars indicate the corresponding 95% range of simulations.
Fig 3.
Impact of vaccination with and without pre-screening on dengue cases.
Percentage of reported dengue cases averted by targeted age groups over a 10-year routine vaccination program with 80% coverage, among the whole population (i.e., population impact) under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios and among vaccinated individuals only (i.e., individual impact) under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, with diagnostic pre-screening versus no screening. Bars represent mean model estimates, and error bars indicate the corresponding 95% range of simulations.
Fig 4.
Impact of vaccination with and without pre-screening on dengue hospitalizations.
Percentage of reported dengue hospitalizations averted by targeted age groups over a 10-year routine vaccination program with 80% coverage, among the whole population (i.e., population impact) under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios and among vaccinated individuals only (i.e., individual impact) under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, with diagnostic pre-screening versus no screening. Bars represent mean model estimates, and error bars indicate the corresponding 95% range of simulations.
Fig 5.
Impact of vaccination on dengue cases and hospitalizations, with and without efficacy against infection.
Percentage of reported dengue cases averted by targeted age groups under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios, and percentage of hospitalizations due to dengue averted by targeted age groups under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, assuming the vaccine has efficacy against infection with any serotype similar to that of Dengvaxia, over a 10-year routine vaccination program with 80% vaccine coverage. Bars represent mean model estimates, and error bars indicate the corresponding 95% range of simulations.